Abstracts Archive - Page 2492 of 2607 - ACR Meeting Abstracts

Abstract Number: 1695 • 2012 ACR/ARHP Annual Meeting
Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data
M. C. Genovese¹, M C. Hochberg², R. B. Cohen³, M. E. Weinblatt⁴, J. Kaine⁵, Edward Keystone⁶, P. Nash⁷, I. Delaet⁸ and R. Alten⁹, ¹Stanford University, Palo Alto, CA, ²Department of Medicine, University of Maryland, Baltimore, MD, ³Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁵Sarasota Arthritis Research Center, Sarasota, FL, ⁶Mount Sinai Hospital, Toronto, ON, Canada, ⁷University of Queensland, Brisbane, Australia, ⁸Bristol-Myers Squibb, Princeton, NJ and Bristol-Myers Squibb, Hopewell, VA, ⁹Schlosspark-Klinik, University Medicine, Berlin, Germany
Background/Purpose: Disease-modifying therapies for RA have proven efficacy, but these drugs may have selective toxicities, such as malignancy, that may increase with duration of treatment.…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1657 • 2012 ACR/ARHP Annual Meeting
Peg-IFNa/Ribavirin/Protease Inhibitor Combination Is Highly Effective in HCV-Mixed Cryoglobulinemia Vasculitis
David Saadoun¹, Stanislas Pol², Pascal Lebray Sr.³, François Blanc⁴, Gilles Pialoux⁵, Alexandre Karras⁶, Dorothée Bazin⁷, Emmanuelle Plaisier⁸ and Patrice Cacoub Sr.⁹, ¹DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ²Hepatology, Cochin Hospital, Paris, France, ³Hepatology, Hôpital Pitié Salpétrière, Paris, France, ⁴hôpital Montpellier, Montpellier, France, ⁵hôpital Tenon, Paris, France, ⁶Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁷Nouvel Hôpital Civil, Strasbourg, France, ⁸Nephrology, Tenon Hospital, Paris, France, ⁹Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: The standard of care treatment of patients presenting a HCV-mixed cryoglobulinemia (MC) vasculitis includes Peg-IFNa plus Ribavirin, w/wo Rituximab. Thirty to 40% of patients…
Abstract Number: 1658 • 2012 ACR/ARHP Annual Meeting
Signal Transducer and Activator of Transcription 3 Induced Synovial Invasion and Migration Is Mediated in Part Through the Notch/Hypoxia-Inducible Factor 1α Pathways
Wei Gao¹, Douglas J. Veale² and Ursula Fearon³, ¹Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ²Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ³Dublin Academic Medical Centre, Translation Rheumatology Research Group, Dublin, Ireland
Background/Purpose: To examine the role of Signal Transducer and Activator of Transcription 3 (STAT3) in mediating synovial cell-cell interactions, migration/invasion and key downstream signaling pathways…
Abstract Number: 1659 • 2012 ACR/ARHP Annual Meeting
Ptpome Profile of Rheumatoid Arthritis Fibroblast-Like Synoviocytes: A Novel Role for the Tyrosine Phosphatase SHP-2 As a Modulator of Invasion and Survival
Stephanie Stanford¹, Michael Maestre², Beatrix Bartok³, David L. Boyle⁴, Heather Arnett⁵, Tomas Mustelin⁶, Gary S. Firestein⁷ and Nunzio Bottini², ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁴Division of Rheumatology, Allergy and Immunology, University of California at San Diego School of Medicine, La Jolla, CA, ⁵Amgen, Inc., Seattle, WA, ⁶Sanford-Burnham Institute for Medical Research, La Jolla, CA, ⁷Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: Fibroblast-like synoviocytes (FLS) in the synovial intimal lining are key mediators of inflammation and joint destruction in rheumatoid arthritis (RA). These cells assume a…
Abstract Number: 1660 • 2012 ACR/ARHP Annual Meeting
Development of a Bruton’s Tyrosine Kinase (Btk) Inhibitor, ONO-4059: Efficacy in a Collagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA)
Toshio Yoshizawa, Yuko Ariza, Yoshiko Ueda, Shingo Hotta, Masami Narita and Kazuhito Kawabata, Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, and tyrosine kinases have key roles in the signaling pathways that regulate…
Abstract Number: 1661 • 2012 ACR/ARHP Annual Meeting
CCR1 Potentiates Gouty Inflammation Following Initial CXCR2-Dependent Neutrophil Recruitment to Sites of Monosodium Urate Crystal Deposition in Mice
Robert P. Friday¹, Terry K. Means², Melissa Tai², Christian D. Sadik² and Andrew D. Luster³, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Charlestown, MA, ³Massachusetts General Hospital, Charlestown, MA
Background/Purpose: During attacks of acute gouty arthritis, monosodium urate (MSU) crystals elicit a potent neutrophilic inflammatory response in the affected joint, causing exquisite pain and…
Abstract Number: 1662 • 2012 ACR/ARHP Annual Meeting
Anti-IL-6 Therapy Impairs Intestinal Repair Through Inhibition of Epithelial Proliferation After Injury
Kristine Kuhn¹, Hiroyuki Miyoshi², Nicholas A. Manieri², Nicole P. Malvin², Vinieth Bijanki², Paul Allen² and Thaddeus S. Stappenbeck², ¹Internal Medicine, Washington University School of Medicine, St. Louis, MO, ²Pathology and Immunology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: Inhibition of IL-6 is used for treatment of rheumatoid arthritis and now being investigated as biologic therapy for a wide variety of autoimmune conditions,…
Abstract Number: 1663 • 2012 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 Is a Key Regulator of Monocyte-Driven Inflammatory Arthritis
Matthew J. Billard¹, Patrick M. Giguére², Brian Buckley², Marcus W. McGinnis¹, Roman Timoshchenko¹, Peng Liu¹, David P. Siderovski² and Teresa K. Tarrant³, ¹Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Monocytes are critical to rheumatoid arthritis (RA) disease pathogenesis and are recruited to the inflamed synovium by inflammation-driven chemokines. G protein signaling modulator 3…
Abstract Number: 1664 • 2012 ACR/ARHP Annual Meeting
Autoantibodies Are Associated with Subclinical Atherosclerosis and Cardiovascular Endpoints in Caucasian and African American Women in a Prospective Study: the Multi-Ethnic Study of Atherosclerosis (MESA)
Darcy S. Majka¹, Rowland W. Chang², Richard M. Pope³, Marius C. Teodorescu⁴, Elizabeth W. Karlson⁵, Thanh Huyen T. Vu⁶, Joseph Kang⁶ and Kiang Liu⁷, ¹Division of Rheumatology, Northwestern University, Chicago, IL, ²Dept Preventive Med, Northwestern University, Chicago, IL, ³Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL, ⁴Microbiology, TheraTest Laboratories Inc, Lombard, IL, ⁵Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Preventive Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL, ⁷Preventive Medicine, Northwestern University, Chicago, IL
Background/Purpose: Although the association between rheumatoid arthritis (RA) and cardiovascular disease (CVD) is established, the exact mechanism is not known. Subjects who later develop RA…
Abstract Number: 1665 • 2012 ACR/ARHP Annual Meeting
Associations of Race and Ethnicity with Overall Mortality and Cardiovascular Events Among Patients with End-Stage Renal Disease Due to Lupus Nephritis
Jose A. Gomez-Puerta¹, Sushrut Waikar², Graciela S. Alarcon³, Jun Liu⁴, Daniel H. Solomon⁵, Wolfgang C. Winkelmayer⁶ and Karen H. Costenbader⁷, ¹Section of Clinical Sciences, Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ²Division of Nephrology, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁶Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Patients with SLE and lupus nephritis (LN) are at elevated risks of cardiovascular disease. Past studies have suggested that African American patients with SLE…
Abstract Number: 1666 • 2012 ACR/ARHP Annual Meeting
Short Term Use of Glucocorticoids Is Not Associated with Acute Risk of Myocardial Infarction
Steven C. Vlad¹, David T. Felson², Donald R. Miller³ and Yuqing Zhang⁴, ¹Clinical Epidemiology, Boston University, Boston, MA, ²Boston University, Boston, MA, ³Center for Health Quality, Outcomes, and Economic Research, Edith Nourse Rogers Memorial VA Hospital, Bedford, MA, ⁴Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Observational studies of both chronic and short term glucocorticoid (GC) use have suggested an elevated risk of acute myocardial infarction (MI). However this could…
Abstract Number: 1667 • 2012 ACR/ARHP Annual Meeting
Impact of Rheumatoid Arthritis On Recognition of Hypertension in a Medically Homed Population
Christie M. Bartels¹, Heather Johnson², Katya Voelker³, Patrick Mc Bride⁴ and Maureen Smith⁵, ¹Rheumatology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ³Univ of Wisconsin School of Medicine and Public Health, Madison, AA, ⁴Cardiology/Medicine, Univ of Wisconsin School of Medicine and Public Health, Madison, WI, ⁵Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI
Impact of Rheumatoid Arthritis on Recognition of Hypertension in a Medically Homed PopulationBackground/Purpose: Numerous studies report increased cardiovascular disease (CVD) events and others describe increased…
Abstract Number: 1668 • 2012 ACR/ARHP Annual Meeting
Improving the Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis with a New Predictive Model Using the 10-Year Prospective Carre-Study
Alper M. van Sijl¹, Inge A.M. van den Oever¹, Mike J.L. Peters², Vokko P. van Halm³, Alexandre E. Voskuyl⁴, Yvo M. Smulders⁵ and Mike T. Nurmohamed¹, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Internal medicine, VU University Medical Center, Amsterdam, Netherlands, ³Cardiology, Academic Medical Centre, Amsterdam, Netherlands, ⁴Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Internal Medicine, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory joint disease which is associated with an increased cardiovascular (CV) risk. Traditional CV risk factors do not…
Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Catrina B. Scherrer¹, Anne AF Mannion², Diego Kyburz³, Markus Vogt⁴ and Ines A. Kramers-de Quervain¹, ¹Rheumatology, Schulthess Clinic, Zürich, Switzerland, ²Research Department, Schulthess Clinic, Zürich, Switzerland, ³Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁴Infectious Diseases Service, Cantonal Hospital Zug, Baar, Switzerland
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].